Laurus Labs Q1 FY27 Earnings Call Transcript Released
Laurus Labs released its Q1 FY27 earnings call transcript. The company reported record quarterly revenue of INR 2,026 crores (up 29%), driven by CDMO growth (INR 835 crores, up 69%) and Affordable Medicines (INR 1,156 crores, up 10%). EBITDA margins improved to 31.8%. Significant investments are being made in capacity expansion for CDMO and new modalities.
The announcement concerns the detailed financial performance and strategic outlook of the company, including significant growth figures and future investment plans, which are material to investors.
The company reported record quarterly revenue, EBITDA, and profits, with strong growth across key segments and improved margins. Management expressed confidence in future growth and value creation.
Laurus Labs Limited has released the transcript of its Q1 FY27 earnings conference call, which was hosted on July 24, 2026. The call featured management including Dr. Satyanarayana Chava (Founder and CEO), Mr. V. V. Ravi Kumar (Executive Director and CFO), and other key executives.
During the call, the management reported significant acceleration in the CDMO business, with sales of INR 835 crores, a growth of 69%. The Affordable Medicines division reported revenues of INR 1,156 crores, an increase of 10% year-on-year. Overall, the company achieved its highest quarterly revenue, EBITDA, and profits, with revenues at INR 2,026 crores, a 29% growth. EBITDA margins expanded to 31.8%, and gross margins were maintained at 62.7%.
Discussions also covered capacity expansions, including investments in peptide and ADC capabilities, and the construction of a commercial-scale fermentation facility for Laurus Bio, expected to be operational by the end of the year. The company reiterated its commitment to investing in portfolio complexity and sustainable technology platforms, with R&D spending at 5.8% of revenue. Management expressed confidence in delivering sustained growth and value creation.
What to do with a filing like this
Laurus Labs Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Laurus Labs Limited. Read the original for the full detail.